New legislation currently being reviewed by the US House of Representatives is aimed at speeding up the approval process for new antibacterial agents. The Antibiotic Development to Advance Patient Treatment Act of 2013 (“ADAPT Act”) is a successor to the Generating Antibiotics Incentives Now (GAIN) Act passed by the US Government in 2013 and reinforces the need to advance drug development in order to combat the growing public health threat of “superbugs”. The ADAPT Act provides incentives for investment and innovation in developing new antibacterial drugs and is another step forward in developing treatments for patients with antibiotic-resistant infections. Dr Bill Love, CEO of Destiny Pharma said “The GAIN act was the first step towards incentivising pharmaceutical companies to develop new antibacterial drugs and the proposed ADAPT Act takes this a step further by reducing the time it takes to get new antibacterial drugs approved and onto the market. The ADAPT Act demonstrates just how seriously the US Government is taking the threat posed by antibiotic-resistant bacteria and we welcome these developments”.